Recent research has provided further evidence supporting the potential of semaglutide, a drug commonly used for managing type 2 diabetes and weight loss, in reducing alcohol consumption among individuals with alcohol use disorder. The drug, marketed under the names Wegovy and Ozempic, acts as a GLP-1 receptor agonist, mimicking a gut hormone that regulates appetite.
A significant breakthrough in this area comes from a randomized clinical trial conducted by researchers at the University of Southern California. The trial involved 48 participants diagnosed with alcohol use disorder, of which 34 were women. Participants were assigned to receive either semaglutide or placebo injections over a nine-week period. The results indicated that those receiving semaglutide reported lower alcohol intake per drinking session and experienced diminished cravings for alcohol.
Christian Hendershot, a lead researcher on the study, noted that no significant adverse effects were observed, suggesting the drug may be safe for this population. The findings align with previous observational studies that suggested a correlation between semaglutide use and reduced alcoholism risk, although those studies did not establish causation.
Experts in the field, including Rong Xu and Ziyad Al-Aly, have described the trial's results as promising, highlighting the need for larger studies to confirm these findings and address questions about long-term effects and the potential for increased drinking after discontinuation of semaglutide. Hendershot cautioned that while initial results are encouraging, individuals should not self-prescribe semaglutide for alcohol-related issues, as effective medications for alcohol use disorder are already available and approved. Further research is necessary before semaglutide can be recommended for this purpose.